Biogen and Sage Therapeutics' zuranolone has ... The biotech has another couple of recent approvals under its belt that have improved its outlook, however, including Aduhelm follow-up Leqembi ...

Biogen and City Therapeutics are to partner for the development of new RNA interference (RNAi) therapies. Leveraging tissue-enhanced delivery technologies, the partnership will concentrate on one ...

Big Biotech Biogen is venturing into the city, paying $16 million in cash to partner up with an RNAi company to build next-gen central nervous system drugs. The research pact—inked with recently ...

Biogen recently announced a collaboration with City Therapeutics, Inc. to develop RNAi therapies for central nervous system diseases, contributing to a 6% share price increase over the past month.

A start-up that launched only 8 months ago has attracted the attention of Biogen, a major developer of neurological drugs. City Therapeutics will develop its namesake cityRNAs—short for cleavage ...

Through the collaboration, City Therapeutics will leverage its next-generation RNAi engineering technologies to develop an RNAi trigger molecule combined with proprietary drug delivery technology from ...

Biogen and City Therapeutics are collaborating to develop select RNAi therapies in a $46 million partnership. City Therapeutics, a private biopharmaceutical company, will offer its RNAi ...

Biogen and City Therapeutics have announced a partnership worth over $1bn to develop new RNAi therapies. The collaboration will initially centre on a single target that “mediates key central nervous ...

Biogen Inc. and City Therapeutics, Inc. announced a strategic collaboration to develop novel RNA interference (RNAi) therapies targeting central nervous system diseases. City Therapeutics will ...

Biogen Inc. (NASDAQ:BIIB), a prominent player in the biopharmaceutical industry specializing in neuroscience and rare diseases, finds itself at a critical juncture. According to InvestingPro ...

5:53 AM ESTHealth Care Sage rejects Biogen’s buyout offer, but says it's open to deals Sage rejects Biogen’s buyout offer, but says it's open to deals ...

Biogen has revealed encouraging phase 2 results with its anti-CD38 antibody felzartamab in rare kidney disease IgA nephropathy (IgAN), which it hopes could join a series of first-in-class ...